Scarica l'app Stockscreener
12.89
3.87%
0.48
Pre-mercato:
12.88
-0.010
-0.08%
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? - MSN
Zymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500 - Kalkine Media
There's Reason For Concern Over Zymeworks Inc.'s (NASDAQ:ZYME) Price - simplywall.st
SG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade) (ZYME) - Seeking Alpha
Bank of America Corp DE Sells 38,030 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Transcript : Zymeworks Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge - MSN
ZYMEZymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results - Revista ADVFN
Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Nuveen Asset Management LLC - Defense World
Zymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLC - Defense World
BNP Paribas Financial Markets Takes $108,000 Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks gets China's conditional approval for biliary tract cancer treatment - MSN
Ameriprise Financial Inc. Sells 15,800 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Announces NMPA Approval of Zanidatamab in China - GlobeNewswire
Zymeworks gets China's conditional nod for BeOne-partnered cancer treatment - Seeking Alpha
Zymeworks Inc. Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-High expression (IHC3+ Biliary Tract Cancer - marketscreener.com
Zymeworks’ Zanidatamab Receives NMPA Approval in China for HER2+ Biliary Tract Cancer - TipRanks
Zymeworks (ZYME) Receives China's Approval for Zanidatamab in Cancer Treatment | ZYME Stock News - GuruFocus
Zymeworks' Zanidatamab Approved in China for HER2-High Expression Biliary Tract Cancer - marketscreener.com
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewswire
Zymeworks Inc. announces the closing of its previously announced underwritten public offering - McCarthy Tétrault
Zymeworks Inc. (NYSE:ZYME) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
What is HC Wainwright’s Forecast for Zymeworks Q2 Earnings? - Defense World
Zymeworks Showcases Oncology Advances at Major Conferences - TipRanks
Zymeworks Inc. Showcases Azymetric™ Platform and Clinical Progress of Ziihera® at ASCO and ESMO Conferences - Nasdaq
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewswire
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewswire Inc.
TD Cowen Initiates Coverage on Zymeworks (NYSE:ZYME) - Defense World
TD Securities Initiates Coverage on Zymeworks (NYSE:ZYME) - Defense World
Zymeworks Announces Participation in Upcoming Investor Conferenc - GuruFocus
Zymeworks to Engage Investors at Upcoming Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Zymeworks Inc. Announces Upcoming Participation in Key Investor Conferences in June 2025 - Nasdaq
Zymeworks Lines Up Triple Conference Presence: Jefferies, Goldman Sachs, and Citi Healthcare Events - Stock Titan
Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Northern Trust Corp - Defense World
TD Securities Initiates Coverage of Zymeworks (ZYME) with Buy Recommendation - Nasdaq
Zymeworks (ZYME) Initiated as a Buy by TD Cowen Due to Strong Pi - GuruFocus
Zymeworks initiated with a Buy at TD Cowen on Ziihera's opportunities - Seeking Alpha
Zymeworks (ZYME) Receives New Buy Rating from TD Securities | ZYME Stock News - GuruFocus
TD Cowen Initiates Coverage on Zymeworks With Buy Rating - marketscreener.com
Zymeworks (ZYME) Gains Favor with Buy Rating from TD Cowen | ZYM - GuruFocus
Zymeworks Presents Preclinical Data on ZW1528 at the American Th - GuruFocus
Zymeworks (ZYME) Reveals Promising Preclinical Results for ZW152 - GuruFocus
Zymeworks Shows Positive Preclinical Data for Experimental Respiratory Imflammation Treatment - marketscreener.com
Zymeworks Unveils Promising Preclinical Data for Novel Respiratory Treatment - TipRanks
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference - The Manila Times
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference | ZYME Stock News - GuruFocus
The Manufacturers Life Insurance Company Sells 1,089 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Price T Rowe Associates Inc. MD Raises Stock Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet - NewsBreak: Local News & Alerts
Analyst Forecasts For Zymeworks Inc. (NASDAQ:ZYME) Are Surging Higher - Yahoo Finance
Analysts Just Shipped A Stunning Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates - simplywall.st
Zymeworks Reports Q1 2025 Financial Results and R&D Progress - TipRanks
Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript - Insider Monkey
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):